Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 investigator-initiated trial of eftilagimod alpha in conjunction with pembrolizumab plus doublet chemotherapy (carboplatin and pemetrexed) in patients with various solid tumors

Next Previous
Trial Profile

Phase 1 investigator-initiated trial of eftilagimod alpha in conjunction with pembrolizumab plus doublet chemotherapy (carboplatin and pemetrexed) in patients with various solid tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Eftilagimod alpha (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary)
  • Indications Adenocarcinoma; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms INSIGHT-003

Most Recent Events

  • 29 Oct 2025 According to an Immutep Limited media release, data from this trial has been presented at ESMO 2025.
  • 20 Oct 2025 Results (at data cut off: 01 September 2025) presented in the Immutep Limited media release.
  • 20 Oct 2025 According to an Immutep Limited media release, company to present data from this study in a poster presentation at the European Society for Medical Oncology (ESMO) Congress 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top